Blindness News and Research

RSS

Get examined during Glaucoma Awareness Month

It happens slowly. Over time, a person's vision will get worse. Until one day, that person can no longer see. Glaucoma is the second leading cause of blindness in the United States and worldwide. Unfortunately, there is no cure. Once a person's vision is lost, it cannot be regained. That is why Dr. Bizer's VisionWorld is encouraging people to get an examination during Glaucoma Awareness Month.

5 Jan 2011

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Researchers identify new biological pathway that contribute to glaucoma

In a study published today in the Proceedings of the National Academy of Sciences, a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.

4 Jan 2011

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

3 Jan 2011

NEI awards Case Western Reserve $10M for study of retinal diseases

The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.

29 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Pepex announces development of combined glucose monitoring and insulin delivery meter

Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level measurement, all contained in a single, palm-sized unit. These meters provide anytime, anywhere tracking and treatment of diabetes.

22 Dec 2010

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Patients with diabetes who follow a self-care regimen generally have success in controlling their disease. But what about patients whose other health conditions, such as cognitive impairment and/or depression, create barriers to effective treatment?

17 Dec 2010

Opinions: Kangaroo care; NTDs, Women's health

New York Times contributing writer Tina Rosen, on the newspaper's "Opinionator" blog, examines the success of a system known as kangaroo care, which has helped to improve the survival rates of premature infants by using skin-to-skin contact with mothers in place of incubators in low-resource settings. The post notes the potential value of such a strategy in poor countries "where pregnant women are unlikely to get the food and care they need," and "low birth weight babies are very common."

16 Dec 2010

Elsevier enables text-to-speech option for all ePub book titles

Elsevier, the world-leading publisher of scientific, technical and medical information products and solutions, announced today that it has enabled the text-to-speech option on all of its ePub book titles. The text-to-speech function enables an e-book to read aloud. This will facilitate access by readers who would otherwise face a range of access challenges through blindness, dyslexia, or motor difficulties.

10 Dec 2010

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors.

10 Dec 2010

Three-day meeting on eliminating river blindness kicks off in Nigeria

A three-day meeting of the WHO African Program for Onchocerciasis (River blindness) Control (WHO/APOC) opened in Abuja, Nigeria, on Tuesday, PANA/Afrique en ligne reports (12/8).

10 Dec 2010

Ameco Medical to commence clinical trials for PNT procedure's reimbursement approval

Sunridge International, announced today that Ameco Medical is preparing to start the short term clinical trials needed for reimbursement approval.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device

Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the US Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.

8 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

32% of UAE residents could have diabetes or prediabetes by 2020

One in three United Arab Emirates (UAE) residents could have diabetes or prediabetes by the end of the decade, according to a new analysis from international health and well-being company UnitedHealth Group, released today at the World Health Care Congress Middle East meeting in Abu Dhabi.

7 Dec 2010

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.

7 Dec 2010

Blindness News and Research

Get examined during Glaucoma Awareness Month

PanOptica completes $30 million Series A financing

Researchers identify new biological pathway that contribute to glaucoma

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

NEI awards Case Western Reserve $10M for study of retinal diseases

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Pepex announces development of combined glucose monitoring and insulin delivery meter

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Exciting progress made in MS research during 2010

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Opinions: Kangaroo care; NTDs, Women's health

Elsevier enables text-to-speech option for all ePub book titles

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

Three-day meeting on eliminating river blindness kicks off in Nigeria

Ameco Medical to commence clinical trials for PNT procedure's reimbursement approval

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

FDA clears Valeritas' V-Go Disposable Insulin Delivery Device

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

32% of UAE residents could have diabetes or prediabetes by 2020

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News